Abstract
Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder with high morbidity and mortality [1] . The incidence of DM is estimated to be 6%-8%, and currently, it is the fourth leading cause of diseaserelated death worldwide [2] . Type 2 diabetes mellitus (T2DM) accounts for 90% of DM cases and is therefore by itself a leading cause of the diabetes epidemic [3, 4] . Increasing evidence has suggested a pathological role for the immune system in affecting insulin secretion, blood glucose levels, and chronic inflammation that are observed in T2DM [5] [6] [7] [8] . It has been shown that, in T2DM, there is a chronic cytokine-mediated inflammation that activates the innate immune system [5] [6] [7] . Cytokines may act on adipose tissue, liver, brain, and pancreatic β-cells, resulting in a disruption in lipid metabolism, thus leading to obesity, insulin resistance, and atherosclerosis that are associated with T2DM [9, 10] .
T lymphocytes, or T cells, belong to a group of white blood cells referred to lymphocytes, and play a central role in cell-mediated immunity [11] . T helper (Th) cells are also known as CD4
+ T cells because they express the CD4 protein on their surface. Th cells assist other white blood cells in the immune response, including aiding in the maturation of B cells into plasma cells, and activation of cytotoxic T cells and macrophages, among other processes. Interestingly, CD4 + T cells play an important role in the initiation of immune responses [12] . Studies have also suggested that Th cells play a role in T2DM. For example, T2DM is correlated with increased frequencies of mycobacterial-antigen specific CD4 + Th1 and Th17 cells in individuals with active pulmonary tuberculosis [13] . Ehiaghe [14] found that T2DM results in an increased production of free radicals, which may be related to the complications associated with nonspecific activation of CD4 + T cells. Zhang and Zang [8] demonstrated that T2DM patients tend to have disorders in cellular immunity, including abnormal CD4 + T levels, which are associated with increased blood glucose levels and decreased insulin secretion capacity. These studies suggest an important role for CD4 + T cells in the progression of T2DM. Myeloid-derived suppressor cells (MDSCs) are a recently described subset of bone marrow-derived cells that suppress T cell responses [15, 16] . This heterogeneous population of cells consists of myeloid progenitor and immature myeloid cells, and can be identified by coexpression of CD33 and CD11b in humans, and CD11b and Gr-1 in mice [17] . Much evidence has suggested that MDSCs may be used as a novel cell-based immunotherapy within the fields of transplantation and autoimmune diseases [18] [19] [20] . In particular, in mouse models of autoimmune diabetes, recent evidence has suggested that MDSCs in therapeutic settings can prevent the development of diabetes. In this study, we aimed to explore the potential role of MDSCs in T2DM progression and to evaluate whether the underlying mechanism was associated with CD4 + T cells.
Materials and Methods

Patients
Twenty-four insulin-treated T2DM patients (30-55 years of age) were diagnosed at the First Affiliated Hospital, Zhengzhou University. Diabetes was diagnosed according to WHO criteria. These patients were non-obese or formally obese with or without a family history of diabetes. All patients were on insulin treatment without diet management, physical exercise, or oral medications. In addition, none of the patients received lipid-lowering medications. None of the patients had any evidence of renal failure as evidenced by a lack of creatinemia, uremia, or macroalbuminuria. Twenty-two healthy subjects were selected from the general healthy population in the same study area as controls, following the same inclusion criteria described previously [21] . Control and diabetic patients were matched with respect to age and body mass index. Informed written consent was obtained from each participant. The protocol was approved by the Ethics Committee of the First Affiliated Hospital, Zhengzhou University.
Detection of serum cytokine levels
Serum samples were obtained from the patients and were immediately stored at −70°C until analyzed. The cytokines interleukin (IL)-4, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, and transforming growth factor-β (TGF-β) were measured using ELISA kits (RapidBio Laboratory, Calabasas, USA) according to the manufacturer's instructions.
Animals
C57BL6J db/db (a T2DM model) and control heterozygous (db/-) male mice (age of 6-7 weeks, weighing 20 ± 2 g) were purchased from the animal laboratory of the Academy of Medical Sciences (Beijing, China). All animals were kept in separate cages and housed under constant temperature and humidity with 12 h light-dark cycles, and had free access to food and water at temperature of 25°C ± 1°C and humidity of 50%. The animal experiment was approved by Ethic Committee of the First Affiliated Hospital, Zhengzhou University.
Isolation, expansion, and purification of human MDSCs
Human peripheral blood mononuclear cells (PBMCs) were isolated from the blood samples of patients by centrifugation at 2700 g for 20 min at 22°C using a Ficoll-Hypaque density gradient (IAE-1). Isolated PBMCs were incubated for 7 days in granulocyte-macrophage colony-stimulating factor (1 ng/ml) and IL-1β (1 ng/ml) to expand MDSCs, as described previously [22] . The CD33 + /CD11b + MDSCs were isolated from the PBMCs using Lin1 and HLA-DR negative selection (Miltenyi Biotech, Bergisch Gladbach, Germany), and were then analyzed using a BD FACS Aria (Becton Dickinson, San Jose, USA). Cells with a purity of over 85% were used in the subsequent experiments.
Isolation of MDSCs and splenocytes from db/db mice C57BL6J db/db mice were sacrificed and their spleen and peripheral blood samples were harvested. Mouse MDSCs were isolated from blood samples of mice using the previously described Percoll protocol [23] . Fraction II containing Gr-1
by a FACSVerse flow cytometry (BD FACSVerse™; BD Biosciences, San Jose, USA). The purity of mouse MDSCs was 98%. Mouse splenocytes were isolated from mouse spleen by mechanical dissociation [24] , and resuspended in RPMI 1640 (Gibco BRL, Gaithersburg, USA) supplemented with 2 mM L-glutamine, 10% heat-inactivated fetal calf serum (Gibco BRL) and 100 μg/ml penicillin/streptomycin, and lysed using 8.3 mg/ml NH 4 Cl to remove red blood cells.
CD4 + T helper cell phenotyping
The frequencies of CD4 + T helper cells were determined by immunostaining with specific monoclonal antibodies (mAbs) combinations. Briefly, PBMCs or splenocytes were stained with the appropriate combination of anti-CD3-FITC/anti-CD4-PerCP (PE) (BD Pharmingen, Le Pont de Claix, France) to identify different T cell sub-populations. After incubation with the appropriate mAbs at 4°C in the dark for 30 min, cells were washed and fixed with FACS lysing solution (BD Pharmingen). The cells were finally resuspended in 300 μl of staining buffer and analyzed using a FACSCalibur four-color flow cytometer (BD Pharmingen) with CellQuest Pro or FlowJo 7.6 software (BD Pharmingen).
Proliferation assay
Carboxyfluorescein succinimidyl ester (CFSE) labeling was used to measure cell proliferation, as previously described [25] . Briefly, 1.3 × 10 6 CD4 + T cells were co-cultured with MDSCs at ratios of 1:1, 2:1, 4:1, and 1:0 in RPMI 1640 medium, supplemented with 10% fetal bovine serum (Gibco Life Technologies, Carlsbad, USA) and stimulated with anti-CD3 (1 μg/ml; Sigma-Aldrich, St Louis, USA) and anti-CD28 (2.5 μg/ml; Sigma-Aldrich) monoclonal antibodies. The cells were harvested following 5 days of culture and stained with anti-CD4-APC antibody (1 μg/ml; Sigma-Aldrich). CFSE dilution was measured by flow cytometry using an LSR Fortessa cell analyzer (BD Biosciences). As the CFSE signal becomes diluted with each cell division, cells exhibiting a low CFSE fluorescence intensity were considered to have proliferated. The cell supernatant was also collected to measure cytokine levels.
NOD/SCID diabetic model 
H&E staining
H&E staining was performed to determine the severity of insulitis. Briefly, pancreatic tissue was fixed with 10% buffered formalin solution and embedded in paraffin before being cut into 6-μm thick sections.
The prepared sections were stained using Mayer's H&E (Yeasen, Shanghai, China) following a routine staining procedure and analyzed with an Olympus BH-2 light microscope (Olympus, Tokyo, Japan).
Statistical analysis
All statistical analyses were performed using SPSS version 13.0 software (SPSS, Inc., Chicago, USA). The data are presented as the mean ± standard deviation (SD) from three independent experiments. Values of P < 0.05 were considered statistically significant. Comparisons between different groups were analyzed using a Mann-Whitney U test.
Results
Increased frequency of CD11b + /CD33 + MDSCs, and CD3-FITC/CD4-PE sorted CD4 + T cells in the peripheral blood of T2DM patients
To determine whether the frequency of MDSCs was altered in the peripheral blood of T2DM patients, peripheral blood was collected from T2DM patients and healthy control subjects. Two surface markers CD11b and CD33 were used to identify CD11b + /CD33 + MDSCs [25] and then the frequency of MDSCs in the peripheral blood of T2DM patients was compared with that in the healthy controls. MDSCs were found to be present at a high frequency in the peripheral blood of T2DM patients, and were significantly lower in the peripheral blood of healthy control subjects (Fig. 1A,B) . In from the peripheral blood of T2DM patients and healthy control subjects. Each circle represents an individual subject (n = 22 in the control group and n = 24 in the T2DM group). *P < 0.05 and ***P < 0.001 vs. Control group.
addition, antibodies to the surface markers CD3 and CD4 (CD3-FITC and CD4-PE respectively) were used to identify CD4 + T cells [21] and the frequency of CD4 + T cells in the peripheral blood of T2DM patients was also compared with that in the healthy controls. It was found that CD4 + T cells were present at a low frequency in the peripheral blood of healthy control subjects and were significantly increased in the peripheral blood of T2DM patients (Fig. 1C,D) .
Decreased IL-4 and increased TNF-α and IFN-γ concentrations in the serum of T2DM patients
To investigate the expression of cytokines secreted from CD4 + T cells in T2DM, serum levels of cytokines including IL-4, IL-10, TNF-α, and IFN-γ were assayed. The serum IL-4 concentration was greatly reduced in T2DM patients compared with control subjects (Fig. 2A) . In addition, there was no significant difference in serum IL-10 levels between T2DM patients and control subjects (Fig. 2B) . However, the concentrations of TNF-α and IFN-γ were markedly increased in T2DM patients, as compared with control subjects (Fig. 2C,D) . These data indicated that CD4 + T cell-mediated immunoregulation was closely related to T2DM.
Increased frequency of CD11b
+ /Gr-1 + MDSCs and CD3-FITC/CD4-PE sorted CD4 + T cells in the splenocytes and peripheral blood of T2DM mice
To determine whether the abundance of MDSCs was changed in the splenocytes and peripheral blood of diabetic db/db mice, the spleen and peripheral blood samples were collected from db/db mice and control mice. The surface markers CD11b and Gr-1 were used to identify CD11b + /Gr-1 + MDSCs [23] and then to determine frequency of MDSCs in the spleen and peripheral blood of these mice. As a result, MDSCs were found to be present at a high frequency in the spleen and peripheral blood of db/db mice, but were significantly lower in control mice (Fig. 3A-C) . Labeled antibodies against the cell surface markers CD3 and CD4 (CD3-FITC and CD4-PE) were also used to identify CD4 + T cells [21] and the frequencies of CD4 + T cells in the spleen and peripheral blood of db/ db mice were compared with that of control mice. CD4 + T cells were found to be present at a low frequency in the spleen and peripheral blood of control mice, but were significantly increased in db/ db mice (Fig. 3D-F) . These data indicated that T2DM mice showed increased frequency of MDSCs and CD4 + T cells in the splenocytes and peripheral blood.
MDSCs inhibit proliferation and modulate cytokine secretion in CD4 + T cells in vitro
To investigate the effects of MDSCs on CD4 + T cells, MDSCs from db/ db mice were sorted and subsequently co-cultured with CFSE-labeled CD4 + T cells from db/db mice at different ratios. After 5 days of culture, the proliferation of the CD4 + T cells was assessed by flow cytometry. The data revealed that, as the cell density of the MDSCs was increased, the proliferation of CD4 + T cells was inhibited (Fig. 4A ). In addition, the effect of MDSCs on cytokine secretion from CD4 + T cells was also assessed using ELISA kits to detect cytokine levels in the culture supernatant. The data showed that the level of TNF-α was significantly decreased; whereas the levels of IL-10 and TGF-β were significantly increased in CD4 + T cells co-cultured with MDSCs, while IL-4 and INF-γ levels kept unchanged, as compared to CD4 + T cells alone ( Fig. 4B-F) . These data indicated that MDSCs inhibited proliferation and modulated cytokine secretion in CD4 + T cells in vitro.
MDSCs delay the development of diabetes in NOD/ SCID mice
To explore whether MDSCs can affect the development of T2DM in a murine model, we adoptively injected NOD/SCID mice with PBS, splenic CD4 + T cells, or CD4 + T cells plus MDSCs. As shown in Then, the extent of leukocyte infiltration in mice was examined at 15 days post cell injection. The extent of leukocyte infiltration is recognized as a hallmark of insulitis. Consistently, the data revealed that compared to the control NOD/SCID mice, NOD/SCID mice that had received a transfer of CD4 + T cells had significantly increased amounts of leukocyte infiltration into the pancreata; in contrast, co-injection with MDSCs significantly decreased the extent of leukocyte infiltration (Fig. 5B) . These data indicated that MDSCs could suppress autoreactive T cells and thereby prevent the development of T2DM in NOD/SCID mice. The effects of MDSCs on cytokine secretion in the pancreata were also examined. Results showed that transfer of MDSCs significantly decreased the levels of TNF-α and IFN-γ, but increased the levels of IL-4 and IL-10 compared to the control mice (Fig. 5C-F) . These data indicated that transfer of MDSCs significantly reversed these effects. The level of IFN-γ was markedly increased in T2DM patients as compared to control subjects. n = 22 in the control group and n = 24 in the T2DM group. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. Control group. of db/db and control mice. n = 10 in each group. *P < 0.05, **P < 0.01 vs. Normal group.
Discussion
In this study, we found that the frequency of CD11b MDSCs group as compared to the CD4 + T group. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. corresponding controls; # P < 0.05 vs. CD4 + T group.
uveoretinitis, and inflammatory bowel disease, suggesting the existence of a novel MDSC-mediated immune regulatory pathway in autoimmune diseases [26] . Yin et al. [23] reported that adoptive transfer of MDSCs derived from mice harboring allogeneic mammary tumor cells partially delays the onset of diabetes. In addition, Hu et al. [27] showed that the expansion of MDSCs is associated with anti-CD20 therapy in mice, which prevents and reverses diabetes. In terms of the frequency of CD4 + T cells in T2DM, Zhang and Zang [8] demonstrated that T2DM patients had significantly lower levels of CD4 + T cells compared with normal controls. In addition, the mean percentage of CD4 + T cells in Iraqi patients with T2DM was significantly decreased compared with healthy controls [28] . In contrast, our study showed the opposite results, which may be due to the different ethnic group and different sample collection methods.
Haile et al. [18] reported that transfer of MDSCs ameliorated symptoms in an inflammatory bowel disease model. MDSCs have also been shown to be capable of inducing immune tolerance in allogeneic bone marrow transplantation [29] . In our study, we showed that MDSCs inhibited the proliferation of CD4 + T cells in vitro.
Consistently, previous studies have also shown that peripheral blood MDSCs from T1D patients inhibit T cell proliferation in a contactdependent manner [23, 30] . We also found that MDSCs could delay the onset of diabetes in NOD/SCID mice, as evidenced by an attenuation of the increase in PG levels. In addition, most of the MDSC-treated mice remained diabetesfree. Consistent with a previous study [23] , the pancreata of MDSCtreated mice showed significantly lower levels of lymphocyte infiltration in islets, and less insulitis as compared with that of the control group. In addition, decreased IL-4 level and increased TNF-α and IFN-γ levels were observed in the sera from T2DM patients. Like their murine counterparts, human CD4 It has been reported that MDSCs can block anti-tumor responses by secreting cytokines such as IL-10, IFN-γ, and TGF-β [31] . Other studies have suggested that MDSCs can promote TGF-β and IL-10 secretion and dramatically inhibit IFN-γ secretion, with no effect on the secretion of IL-4 [32] . These conflicting results need to be further investigated. Our results showed that the level of TNF-α was decreased, while those of IL-10 and TGF-β were increased in the supernatant of a co-culture of CD4 + T cells and MDSCs, compared with that of CD4 + T cells alone.
However, it is unclear whether the increased concentrations of IL-10 and TGF-β are due to the unidirectional influence of MDSCs on cytokine secretion of CD4 + T cells or due to secretion by MDSCs itself, because MDSCs can also secrete immunosuppressive cytokines including IL-10 and TGF-β. This is a limitation of our study, and further investigation is required. In summary, this study demonstrated that MDSCs could suppress CD4 + T cell activity and prevent the development of T2DM;
hence, these cells may emerge as effective candidates for the treatment of T2DM.
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